You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 23, 2024

~ Buy the PARSABIV (etelcalcetide) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR PARSABIV

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for parsabiv

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02833857 ↗	A Single-dose Study in Paediatric Patients Aged 2 to Less Than 18 Years With Secondary Hyperparathyroidism (sHPT) Receiving Haemodialysis	Completed	Amgen	Phase 1	2017-03-14	This is a study to evaluate the safety and pharmacokinetics in pediatric patients with secondary hyperparathyroidism receiving a single dose of etelcalcetide at the end of hemodialysis.
NCT03633708 ↗	Study of Etelcalceide in Pediatric Subjects With Secondary Hyperparathyroidism and CKD on Hemodialysis	Recruiting	Amgen	Phase 3	2019-04-29	Study of Etelcalcetide in Pediatric Subjects With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis
NCT03795558 ↗	A Study to Investigate the Influence of PTH-lowering by Etelcalcetide (Parsabiv®) on the Calcification Propensity of Serum in Dialysis Patients	Active, not recruiting	Amgen	Phase 2	2019-05-01	This is a single-center, prospective, dose-escalation, pilot study in 15 end-stage renal disease patients on chronic hemodialysis with secondary hyperparathyroidism.
NCT03795558 ↗	A Study to Investigate the Influence of PTH-lowering by Etelcalcetide (Parsabiv®) on the Calcification Propensity of Serum in Dialysis Patients	Active, not recruiting	Prim. Priv. Doz. Dr. Daniel Cejka	Phase 2	2019-05-01	This is a single-center, prospective, dose-escalation, pilot study in 15 end-stage renal disease patients on chronic hemodialysis with secondary hyperparathyroidism.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for parsabiv

Condition Name

Chart
Table

Condition Name for parsabiv
Intervention	Trials
End Stage Renal Disease	1
Hyperparathyroidism; Secondary, Renal	1
Renal Osteodystrophy	1
Secondary Hyperparathyroidism	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for parsabiv
Intervention	Trials
Hyperparathyroidism	3
Renal Insufficiency, Chronic	3
Kidney Diseases	3
Hyperparathyroidism, Secondary	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for parsabiv

Trials by Country

Map
Table

Trials by Country for parsabiv
Location	Trials
United States	13
Malaysia	3
India	3
Argentina	2
Taiwan	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for parsabiv
Location	Trials
New York	2
Missouri	2
California	2
Utah	1
Texas	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for parsabiv

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for parsabiv
Clinical Trial Phase	Trials
Phase 3	1
Phase 2	2
Phase 1	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for parsabiv
Clinical Trial Phase	Trials
Recruiting	2
Completed	1
Active, not recruiting	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for parsabiv

Sponsor Name

Chart
Table

Sponsor Name for parsabiv
Sponsor	Trials
Amgen	3
Prim. Priv. Doz. Dr. Daniel Cejka	1
Thomas Nickolas, MD MS	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for parsabiv
Sponsor	Trials
Industry	3
Other	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.